Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories



Jason M. Melear, M.D.

Jason M. Melear, M.D.

Provider Type: Physician

  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Internal Medicine


  • 1987-1991, Bachelor of Arts in Biology, University of Texas at Austin
  • 1992-1996, MD, Texas Tech University School of Medicine
  • 1996-1999, Resident, Internal Medicine, Baylor University Medical Center, Dallas, Texas
  • 1999-2001, Fellow, Oncology, Baylor University Medical Center, Dallas, Texas

Research Interest

He has a strong interest in research with special focus in hematologic malignancies and Phase I trials.

  • Principal investigator in Austin area Myeloma, Lymphoma, and Leukemia trials.
  • Principal Investigator multiple Austin area Phase I trials.

Medical Practice

  • Texas Oncology Board of Directors 2011-2014
  • US Oncology Hematology Research Committee 2013-present
  • US Oncology Phase I Research Committee 2014-Present
  • Austin Area Research Leader 2014-present
  • Area Director Austin 2015-present

Other Information

Dr. Melear was born in Louisville, Kentucky and moved to Houston, Texas while in high school. He is married and has three children. He enjoys spending time with his family and traveling.


  • Phase IIIB randomized study of lenalidomide and rituximab followed by maintenance in relapsed/refractory non Hodgkins lymphoma in patients with double refractory or early relapsed follicular lymphoma

    Journal of Clinical Oncology, 2017

  • BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC)

    Journal of Clinical Oncology, 2017

  • MAGNIFY: Phase IIIB randomized study of lenalidomide and rituximab followed by lenalidomide versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone, and mantle cell lymphoma.

    American Society of Hematology, 2016

  • Ublituximab in combination with ibrutinib is highly active in patients with relapsed and/or refractory mantle cell lymphoma. Results of a Phase II trial.

    Blood, 2015